Pharmaceuticals, Biotechnology and Life Sciences
Allergy Therapeutics has begin its G205 Phase II study to check the dose-response and safety of its ultra-short course, aluminium…
On Wednesday, STA said the center will allow the introduction of transition metal catalyst-screening technology to their existing small molecule…
CPhI Worldwide report states the current drugs pipeline is discouraging and slowing simple manufacturing innovations. This was announced in its…
AstraZeneca and Merck said Wednesday that th eUS Food and Drug Administration (FDA) has accepted and granted priority review for a…
Silence Therapeutics got the US Patent and Trade Mark Office on Tuesday, after previously reporting issuance of a notice of allowance…
Novartis on Wednesday announced long-term study results supporting the positive safety and efficacy of Revolade in adults with chronic immune…
Horizon Pharma has been named one of the 2017 Best Small & Medium Workplaces by FORTUNE and Great Place to Work for the second year…
Gilead Sciences has promoted Alessandro Riva, MD, to Executive Vice President, Oncology Therapeutics, with responsibility for Gilead’s hematology and oncology programs,…
The US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for AstraZeneca’s Imfinzi (durvalumab) for the treatment of…
Frank Staud assumed the role of Executive Vice President Corporate Communications, Branding and Sponsoring on October 1. The 48-year old…